3 recruiting, 1 terminated. 4 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Recruiting 3, Terminated 1 |
| Phase 1 | 3 | Recruiting 2, Terminated 1 |
Follow Medulloblastoma Recurrent: new trials by email Literature Review of Medulloblastoma Recurrent trials Research Report on Medulloblastoma Recurrent
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease Liothyronine (L-T3), Bevacizumab, Irinotecan - Medulloblastoma, Medulloblastoma, Childhood | Phase 1 / Phase 2 | Recruiting | Sabine Mueller, MD, PhD | 69 | 2026-08-21 | 2026-09-28 |
| Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). Olaparib; 177Lu-DOTATATE - Solid Tumor Cancer, Medulloblastoma | Phase 1 / Phase 2 | Recruiting | Fundación de investigación HM | 25 | 2024-09-20 | 2026-06-04 |
| Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery CX 4945 - Medulloblastoma, Childhood, Medulloblastoma Recurrent | Phase 1 / Phase 2 | Terminated | Pediatric Brain Tumor Consortium | 21 | 2019-07-25 | 2026-10-19 |
| Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors Bevacizumab, Thalidomide, Celecoxib - Medulloblastoma Recurrent, Ependymoma Recurrent | Phase 2 | Recruiting | Medical University of Vienna | 232 | 2014-04-01 | 2026-10-13 |
Medulloblastoma (4) · Ependymoma (2) · Recurrence (2) · Adrenal Cortex Neoplasms (1) · Adrenal Gland Neoplasms (1) · Esthesioneuroblastoma, Olfactory (1) · Glioblastoma (1) · Glioma (1) · Meningioma (1) · Microphthalmia, Isolated, with Coloboma 5 (1) · Neuroblastoma (1) · Neuroendocrine Tumors (1) · Osteosarcoma (1) · Paraganglioma (1) · Pheochromocytoma (1)
Neoplasms (4) · Neoplasms by Histologic Type (4) · Neoplasms, Germ Cell and Embryonal (4) · Neoplasms, Glandular and Epithelial (4) · Neoplasms, Nerve Tissue (4) · Neoplasms, Neuroepithelial (4) · Neuroectodermal Tumors (4) · Neuroectodermal Tumors, Primitive (4) · Glioma (3) · Disease Attributes (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Adrenal Cortex Diseases (1) · Adrenal Gland Diseases (1) · Astrocytoma (1)
Bevacizumab (2) · Irinotecan (2) · Temozolomide (2) · Celecoxib (1) · Cyclophosphamide (1) · Cytarabine (1) · Etoposide (1) · Thalidomide (1) · Triiodothyronine (1) · Vascular Endothelial Growth Factor A (1) · fenofibric acid (1) · lutetium Lu 177 dotatate (1) · olaparib (1) · silmitasertib (1)
Fundación de investigación HM (1) · Medical University of Vienna (1) · Pediatric Brain Tumor Consortium (1) · Sabine Mueller, MD, PhD (1)
United States (3) · Spain (2) · Austria (1) · Czechia (1) · Denmark (1) · France (1) · Norway (1) · Sweden (1)
Amedeo A Azizi, MD (1) · Andreas Peyrl, MD (1) · Marta Osuna Marco, PhD (1) · Ralph Salloum, MD (1) · Sabine Mueller (1)
UM1CA081457 (1)